Thema 1
Investigating the influence of Calreticulin (CALR) mutations on cellular phenotypes
Leitung und Betreuung der Masterarbeit
PD Dr. med. Alexandre Theocharides
Leitung Klinik für Medizinische Onkologie und Hämatologie
Prof. Dr. med. Markus G. Manz
Konzept
Background: CALR mutations are often found in myeloproliferative neoplasms (MPN), a group of hematopoietic stem cell diseases. Apart from activation of JAK/STAT signaling in mutated cells, little is known about the cellular consequences of mutation of this chaperone protein.
Current status of the project: preliminary data from unbiased proteomics screens have shown significant differences between CALR-mutated and CALR-wildtype cells. The exact relevance of these mutations still needs to be determined.
Aim: determining the influence of inducing CALR mutations in CRISPRed cell lines and primary (transduced) patient material to comprehensively determine phenotypes and their potential relevance for driving MPN disease.
Main techniques: CRISPR, FACS, survival assays, siRNA, Western Blot, RT-qPCR
Potential addition, to be discussed: compare effects of CALR mutations to JAK2 mutations, a second well-known driver mutation of MPN, using primary (transduced) patient material or generated or obtained JAK2-mutated cell lines.
Studiendesign:
Methodik:
Zeitplan sofort oder nach Vereinbarung
Bei Interesse kontaktieren Sie bitte: alexandre.theocharides@usz.ch
Thema 2
A
real-world retrospective, non-interventional observational study, utilizing
secondary data collection from medical records/applicable registries (between
2010-2017) of patients with stage III NSCLC
Leitung und Betreuung der Masterarbeit
PD Dr. med. Alessandra Curioni
Leitung Klinik für Medizinische Onkologie und Hämatologie
Prof. Dr. med. Markus G. Manz
Konzept
The aim of this study is to
describe and characterize the stage III NSCLC population based on secondary
data collection, in a longitudinal real-world setting.
Primary Objectives:
1. To describe demographics
and clinical characteristics, previous and subsequent treatment strategies,
healthcare resource utilisation among stage III NSCLC patients
2. To calculate overall
survival, defined as time from stage III diagnosis to death, end of study, or
loss to follow up (whichever occurs first) for stage III patients
Studiendesign:
Methodik:
Zeitplan sofort oder nach Vereinbarung
Bei Interesse kontaktieren Sie bitte: alessandra.curioni@usz.ch,
panagiota.papageorgiou@usz.ch
